Tetraphase Pharma (TTPH) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Tetraphase Pharmaceuticals (TTPH) PT Raised to $7 at Stifel Following 4Q Report
March 9, 2017 9:26 AM ESTStifel raised its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $7.00 (from $5.00) while maintaining a Hold rating. TTPH reported a net loss of $20M, or $(0.61)/share, wider than the Consensus of $(0.55).
Analyst Stephen Willey commented, "We continue to find TTPH shares... More



